Barbara Melotti

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Perspectives on cancer therapy-induced mucosal injury

Environmental-sensitive micelles based on poly(2-ethyl-2-oxazoline)-b-poly(l-lactide) diblock copolymer for application in drug delivery

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Escalating drug delivery in cancer chemotherapy: A review of concepts and practice —Part 2

A review of stimuli-responsive nanocarriers for drug and gene delivery

Dermatologic Reactions to Immune Checkpoint Inhibitors

Anthrazykline in der Krebstherapie

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Epirubicin

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the seventh world conference on lung cancer

Tumour burden and efficacy of immune-checkpoint inhibitors

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients A Hellenic Cooperative Oncology Group Study

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway

Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity

Trends in the Aggressiveness of Cancer Care Near the End of Life

Anthraquinones As Pharmacological Tools and Drugs

High-dose epiribicin for untreated patients with advanced tumours: a phase I study

A Phase II Study of Carboplatin and Cyclophosphamide in Advanced Ovarian Carcinoma

Chemotherapy with Cisplatin, Epirubicin, Methotrexate in the Treatment of Locally Advanced or Metastatic Transitional Cell Cancer of the Bladder (TCC)

Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study

Activity of high-dose epirubicin in advanced non-small cell lung cancer

Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study

Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors